The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?

(2012) Fabio P. S. Santos et al.   Anti-Cancer Agents in Medicinal Chemistry

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

(2012) Anna Yarilina et al.   ARTHRITIS AND RHEUMATISM

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

(2012) Stefanie Andrea Erika Held et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis

(2012) Naresh Punwani et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone

(2011) G. Kock et al.   BLOOD

Janus kinase/signal transducer and activator of transcription 3 signaling pathway is crucial in chemokine production from hepatocytes infected by dengue virus

(2011) Yi-Ting Tsai et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

(2011) Jordan S. Fridman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production

(2010) Michael Conzelmann et al.   BIOCHEMICAL PHARMACOLOGY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Bioluminescence imaging allows measuring CD8 T cell function in the liver

(2010) Dirk Stabenow et al.   HEPATOLOGY

Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs

(2010) Verena Semmling et al.   NATURE IMMUNOLOGY

Loss of Jak2 Selectively Suppresses DC-Mediated Innate Immune Response and Protects Mice from Lethal Dose of LPS-Induced Septic Shock

(2010) Jixin Zhong et al.   PLoS One

Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion

(2009) B. Jahrsdorfer et al.   BLOOD

Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone

(2009) K. von Schwarzenberg et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Jak3 Is Involved in Dendritic Cell Maturation and CCR7-Dependent Migration

(2009) Ana Rivas-Caicedo et al.   PLoS One

Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells

(2008) Frank Grünebach et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY